MCM
TEVA icon

Monarch Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Monarch Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-17,200
Closed -$571K – 94
2017
Q2 		$571K Hold
17,200
– – 0.22% 69
2017
Q1 		$552K Sell
17,200
-5
-0% -$171 0.2% 68
2016
Q4 		$624K Sell
17,205
-435
-2% -$17.4K 0.23% 68
2016
Q3 		$812K Buy
17,640
+50
+0.3% +$2.61K 0.31% 64
2016
Q2 		$884K Buy
17,590
+1,505
+9% +$80.1K 0.33% 62
2016
Q1 		$861K Buy
16,085
+835
+5% +$49K 0.31% 63
2015
Q4 		$1M Hold
15,250
– – 0.38% 60
2015
Q3 		$861K Buy
15,250
+398
+3% +$25.8K 0.35% 61
2015
Q2 		$878K Buy
14,852
+652
+5% +$40.2K 0.34% 63
2015
Q1 		$885K Buy
14,200
+250
+2% +$14.5K 0.33% 62
2014
Q4 		$802K Buy
13,950
+400
+3% +$22.3K 0.3% 66
2014
Q3 		$728K Buy
13,550
+1,700
+14% +$90.1K 0.29% 66
2014
Q2 		$621K Buy
11,850
+150
+1% +$7.67K 0.24% 67
2014
Q1 		$618K Buy
11,700
+750
+7% +$34.7K 0.24% 66
2013
Q4 		$439K Buy
10,950
+1,750
+19% +$68.9K 0.17% 72
2013
Q3 		$348K Buy
9,200
+1,600
+21% +$62.4K 0.15% 76
2013
Q2 		$298K Buy
+7,600
New +$296K 0.13% 80

Other funds holding TEVA

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Monarch Capital Management's TEVA Position: Q3 2017 in Review

Monarch Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q3 2017, closing a stake of 17,200 shares — an estimated $571K sold.

Monarch Capital Management first reported a position in TEVA in Q2 2013 and held it in 17 quarters. The position peaked at $1M in Q4 2015. 535 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

  • Monarch Capital Management reported no remaining Teva Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Monarch Capital Management sold 17,200 Teva Pharmaceuticals shares in Q3 2017, an estimated $571K.
  • Monarch Capital Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 17 quarters.
  • Monarch Capital Management's Teva Pharmaceuticals position peaked at $1M in Q4 2015.
  • 535 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2017.

Based on Monarch Capital Management's 13F filing for Q3 2017, filed 18 Oct 2017.